Creo Medical

The company's core business revolves around the development and commercialization of minimally invasive surgical devices. It leverages a proprietary energy platform, CROMA, which uniquely combines bipolar radiofrequency for localized cutting and high-frequency microwave energy for controlled coagulation and ablation of tissue. This technology is designed to provide surgeons with greater precision and control during procedures, aiming to improve patient outcomes and reduce recovery times. Creo Medical primarily serves the field of therapeutic endoscopy, with a focus on the gastrointestinal (GI) tract. Its business model appears to be centered on the direct sale of its devices and platform to hospitals and clinics. The company generates revenue through the sale of its suite of advanced energy devices, including the Speedboat Inject, which is designed for endoscopic submucosal dissection (ESD), a procedure to remove precancerous and cancerous lesions from the GI tract.

The flagship product line operates on the CROMA platform, an advanced energy generator that powers a range of endoscopic devices. The key device, Speedboat Inject, integrates several functions into one instrument: it can dissect tissue with radiofrequency energy, deliver controlled microwave coagulation, and has an in-built needle for injecting fluid to lift lesions, making complex procedures more streamlined. This multi-functionality is a distinct feature, as it minimizes the need for instrument exchange during surgery, potentially shortening procedure times and associated risks. Beyond the GI tract, Creo Medical is expanding its technology's application into other surgical areas, such as laparoscopy, and has developed a portfolio of products aimed at soft tissue ablation in various organs, including the liver, kidney, and pancreas.